Table 3.
Summary of CUA of CKD patients undergoing kidney transplant included in the review
| Study | Country | Year | Perspective | Discount rate (%) | Time horizon | Model structure |
|---|---|---|---|---|---|---|
| CUA of transplanting infectious kidneys (n = 03) | ||||||
| Kadatz et al. [26] | Canada | 2018 | Health- care payer and Societal | 1.5 | 10 years | Markov decision model |
| Kiberd et al. [27] | Canada | 1994 | Not explicitly stated (Health- care payer costs identified) | 5 | 20 years | Not explicitly stated (Markov decision model identified) |
| Schweitzer et al. [34] | USA | 2007 | Societal perspective | 3 | 20 years | Markov decision model |
| CUA of kidney allocation policies (n = 09) | ||||||
| Axelrod et al. [21] | USA | 2018 | Health- care payer | 3 | 10 years | Discreet Event Simulation |
| Smith et al. [35] | USA | 2015 | Health- care payer | 3 | 20 years | Markov decision model |
| Mutinga et al. [31] | USA | 2005 | Not explicitly stated (Health- care payer costs identified) | 5 | 20 years | Markov decision model |
| Schnitzler et al. [33] | USA | 2003 | Health- care payer | 5 | 20 years | Markov decision model |
| Bavanandan et al. [23] | Malaysia | 2015 | Health- care payer | 3 | Life time | Not explicitly stated (Markov decision model identified) |
| Snyder et al. [36] | USA | 2010 | Societal perspective | 3 | 10 years | Markov decision model |
| Cavallo et al. [24] | Italy | 2014 | Health- care payer | 3.5 | 05 years | Markov decision model |
| Barnieh et al. [22] | Canada | 2013 | Health- care payer | 5 | Life time | Markov decision model |
| Matas et al. [29] | USA | 2003 | Societal perspective | 5 | 20 years | Markov decision model |
| CUA of technology used in KT (n = 04) | ||||||
| Nguyen et al. [32] | Australia | 2015 | Health- care payer | 5 | 20 years | Markov decision model |
| McLaughlin et al. [30] | Canada | 2006 | Health- care payer | 5 | 25 years | Markov decision model |
| Groen et al. [25] | Europe | 2012 | Health- care payer | 4 | 10 years | Markov decision model |
| Liem et al. [28] | Netherlands | 2003 | Societal perspective | 3 | Life time | Markov decision model |
HCV NAT Hepatitis C nucleic acid test, CDC IRDs Centers for Disease Control classified increased risk donors, KDPI Kidney Donor Profile Index, ECD expanded criteria donor, SD standard donor, LKT living kidney transplant, DKT deceased kidney transplant, DBD donation after brain death,DCD donation after cardiac death, CDC complement-dependent cytotoxicity